Day: November 14, 2023

Avicanna Reports Q3 2023 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Acquisition of Medical Cannabis by Shoppers assets leading to the launch of MyMedi.ca.Record revenue of $6.27M, representing an increase of 90% over Q2, and 713% year-over-year.Improvements in performance including 46% consolidated gross margins and adjusted EBITDA of ($400k) TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the commercialization of proprietary cannabinoid-based products and medical cannabis care platform is pleased to announce the results of Q3 2023. “We had the boldness to take on the challenge of acquiring the Medical Cannabis by Shoppers business and executed on integrating it into the newly developed MyMedi.ca to with a goal of being able to offer a comprehensive medical cannabis care platform and...

Continue reading

Dada Announces Unaudited Third Quarter 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

SHANGHAI, China, Nov. 14, 2023 (GLOBE NEWSWIRE) — Dada Nexus Limited (NASDAQ: DADA, “Dada” or the “Company”), China’s leading local on-demand delivery and retail platform, today announced its unaudited financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights Total net revenues in the third quarter were RMB2,866.6 million, an increase of 20.4% year over year from RMB2,380.1 million in the same period of 2022. Total Gross Merchandise Volume (“GMV”) of JDDJ for the twelve months ended September 30, 2023 was RMB73.1 billion, an increase of 24.0% year over year from RMB58.9 billion in the same period of 2022. “We are delighted to report another quarter of robust growth and significant year-over-year margin improvement,” said Mr. Jeff He, President of Dada. “Along the path to achieving our mission...

Continue reading

CPI Aerostructures Reports Third Quarter and Nine Month 2023 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Third Quarter 2023 vs. Third Quarter 2022 Revenue of $20.4 million compared to $20.2 million; Gross profit of $3.7 million compared to $5.3 million; Gross margin of 18.2% compared to 26.4%; Net income of $0.3 million compared to $1.9 million; Earnings per diluted share of $0.02 compared to $0.15; Cash flow from operations of $0.0 million compared to $2.9 million. Nine Months 2023 vs. Nine Months 2022 Revenue of $63.0 million compared to $59.3 million; Gross profit of $13.0 million compared to $12.4 million; Gross margin of 20.6% compared to 21.0%; Net income of $2.4 million compared to $2.3 million ($3.1 million excluding first quarter severance accrual of $0.8 million); Earnings per diluted share of $0.19 compared to $0.19 ($0.25 excluding first quarter severance accrual of $0.06); Cash flow from operations of $0.8 million compared...

Continue reading

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease, expect to initiate Phase I/IIa by year end – SNK02 Phase I allogeneic clinical program continues to progress; anticipated preliminary solid tumor data readout and IND filing for Parkinson’s Disease in 1Q24 SANTA ANA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (Nasdaq: NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (NK) cell therapeutics, today announced its financial results for the third quarter ended September 30, 2023, and provided business highlights. “We had a very exciting quarter as a newly Nasdaq-listed company,” said Paul...

Continue reading

Super League Announces Third Quarter 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Q3 2023 Highlighted by: Record Revenue Growth, New Roblox Partnership to Boost Marketing Strategy, and the Largest Deal in Company History SANTA MONICA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE), a global leader in providing immersive experiences across the world’s largest digital social platforms, has released its third quarter 2023 financial results in the form of a shareholder letter. A webinar hosted by Ann Hand, CEO of Super League, and Clayton Haynes, CFO of Super League, will be streamed here beginning today Tuesday, November 14, 2023 at 5:00 PM Eastern Time to further discuss the results. Management Commentary by Chief Executive Officer, Ann Hand: “In the third quarter, we continued to validate the success of our business model and operational strategy, delivering record quarterly company...

Continue reading

ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Key Corporate Highlights: Progressing toward Q1-2024 initiation of a proof-of-concept clinical trial with Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD). Granted a European patent covering use of VAR 200 (2-hydroxypropyl-beta-cyclodextrin) in diabetic nephropathy/diabetic kidney disease. Nearing completion of pre-clinical requirements for GLP toxicology studies and subsequent IND submission. WESTON, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today provides a corporate update, and reports financial results for the third quarter of 2023 ending September 30, 2023. “The...

Continue reading

Homology Medicines Reports Third Quarter 2023 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

– Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 – BEDFORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates. Homology recently shared a summary of safety and efficacy data on the first dose cohort of the pheEDIT clinical trial evaluating the Company’s HMI-103 gene editing candidate for the treatment of phenylketonuria (PKU). Despite the encouraging HMI-103 clinical data, based on the current financing environment and the anticipated clinical development timeline, Homology announced in July 2023 that it would not pursue any further development of its programs, including HMI-103, and instituted a related workforce...

Continue reading

XWELL, Inc. Reports Third Quarter 2023 Results

Written by Customer Service on . Posted in Public Companies.

XWELL, Inc. Brands XWELL, Inc. Brands Airport Spas Deliver Strong 39% Year-Over-Year Q3 Revenue GrowthNaples Wax Center Acquisition Accelerates Future Off-Airport Growth OpportunitiesFurther Airport Spa Expansion Internationally NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today reported results for the third quarter ended September 30, 2023. Financial and Business Highlights: The Company’s airport XpresSpa business segment delivered revenue growth of approximately 39% versus the comparable quarter in 2022. The Company continues to focus on reducing its cost structure and simplifying its processes in order to reach profitability in 2024. The Company realized the first milestone of its out...

Continue reading

Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

Written by Customer Service on . Posted in Public Companies.

SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives. “Since our founding, Atreca has leveraged a unique discovery platform to identify numerous antibodies binding novel targets in oncology, as well as infectious and autoimmune disease,” said John Orwin. “We remain focused on advancing APN-497444 through preclinical...

Continue reading

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Written by Customer Service on . Posted in Public Companies.

Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET BOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the third quarter ended September 30, 2023 and highlighted recent developments. “We are very pleased with the progress of the last quarter,” noted Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. “Our efforts to improve drug delivery for protein kinase inhibitors brought IkT-001Pro to pre-NDA stage just 15 months after opening...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.